A multi-institutional clinical trial conducted at the UNC Lineberger Comprehensive Cancer Center and 21 other U.S. sites found that a single administration of autologous tumor-infiltrating lymphocyte ...

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

Until recently, solid tumors — which make up 90% of cancer diagnoses — had no cell therapy. However, that changed in 2024, when the FDA approved a treatment from Iovance Biotherapeutics for advanced ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks to Invest In According to Billionaires. Recently, ...

I'm leading the clinical development organization for KSQ. We have two Phase I/II trials investigating our CRISPR-engineered TIL (eTIL) products, KSQ-001EX and KSQ-004EX. TIL therapy harnesses a ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...

A UF Health oncologist answers the most common questions about cell therapy, from who qualifies to how it differs from ...